2026-2030年全球放射性药物市场

全球放射性药物市场预计在2025年至2030年间成长77.583亿美元，预测期内复合年增长率（CAGR）为12.3%。本报告对全球放射性药物市场进行了全面分析，包括市场规模和预测、趋势、成长要素和挑战，以及对约25家公司的供应商分析。

该报告对当前市场状况、最新趋势和驱动因素以及整体市场环境进行了最新分析。市场成长的驱动因素包括神经系统疾病发生率上升、癌症病例数量增加、肿瘤市场投资成长、放射性药物副作用极小。

本研究采用客观的方法，结合一手和二手讯息，包括来自主要行业相关人员的意见。报告包含全面的市场规模数据、区域細項分析、供应商格局以及对主要企业的分析。报告提供历史数据和预测数据。

该研究指出，迴旋加速器放射性药物生产是未来几年推动全球放射性药物市场成长的主要因素之一，新兴经济体新放射性药物的发现和开发以及医疗保健基础设施的改善预计将导致市场需求大幅增加。

目录

第一章执行摘要

第二章 Technavio 分析

• 价格、生命週期、顾客购买篮、采用率和购买标准分析
• 投入与差异化因素的重要性
• 混淆来源
• 驱动因素和挑战的影响

第三章 市场情势

• 市场生态系统
• 市场特征
• 价值链分析

第四章 市场规模

• 市场定义
• 市场区隔分析
• 2025年市场规模
• 2025-2030年市场展望

第五章 市场规模表现

• 2020-2024年全球放射性药物市场
• 2020-2024年原料细分市场分析
• 2020-2024年最终用户细分市场分析
• 应用细分市场分析 2020-2024
• 2020-2024年区域市场分析
• 2020-2024年国家细分市场分析

第六章 定性分析

• 人工智慧对全球放射性药物市场的影响

第七章五力分析

• 五力分析概述
• 买方的议价能力
• 供应商的议价能力
• 新进入者的威胁
• 替代品的威胁
• 竞争威胁
• 市场状况

8. 按来源分類的市场区隔

• 比较：按来源
• 迴旋加速器
• 核子反应炉
• 按来源分類的市场机会

9. 按最终用户分類的市场细分

• 比较：按最终用户
• 诊断
• 治疗药物
• 按最终用户分類的市场机会

第十章 按应用程式进行市场细分

• 比较：按应用
• 肿瘤学
• 循环系统
• 神经病学
• 按应用分類的市场机会

第十一章 客户情况

第十二章 区域情势

• 区域细分
• 区域比较
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 俄罗斯
  • 荷兰
  • 西班牙
• 亚洲
  • 中国
  • 日本
  • 印度
  • 韩国
  • 印尼
  • 新加坡
  • 泰国
• 世界其他地区
  • 澳洲
  • 巴西
  • 沙乌地阿拉伯
  • 南非
  • 阿拉伯聯合大公国
  • 土耳其
• 各区域的市场机会

第十三章：驱动因素、挑战与机会

• 市场驱动因素
• 市场挑战
• 驱动因素和挑战的影响
• 市场机会

第十四章 竞争格局

• 概述
• 竞争格局
• 令人困惑的局面
• 产业风险

第十五章 竞争分析

• 公司简介
• 企业排名指数
• 公司市场定位
• Bayer AG
• Bracco SpA
• Cardinal Health Inc.
• Curium Pharma
• Eckert and Ziegler AG
• GE Healthcare Technologies
• IBA Radiopharma Solutions
• Jubilant Pharma Ltd.
• Lantheus
• NorthStar Medical Radioisotopes
• Novartis AG
• NTP Radioisotopes SOC Ltd.
• PharmaLogic Holdings Corp.
• Siemens Healthineers AG
• Sinotau Pharmaceuticals

第十六章附录

The global radiopharmaceuticals market is forecasted to grow by USD 7758.3 mn during 2025-2030, accelerating at a CAGR of 12.3% during the forecast period. The report on the global radiopharmaceuticals market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of neurological disorders, growing cancer cases and rising investment in oncology market, minimal side effects of radiopharmaceuticals.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global radiopharmaceuticals market is segmented as below:

By Source

• Cyclotrons
• Nuclear reactors

By End-User

• Diagnostics
• Therapeutics

By Application

• Oncology
• Cardiology
• Neurology

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • The Netherlands
  • Spain
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the production of cyclotron-based radiopharmaceuticals as one of the prime reasons driving the global radiopharmaceuticals market growth during the next few years. Also, discovery and development of new radiopharmaceuticals and improvement in healthcare infrastructure in emerging economies will lead to sizable demand in the market.

The report on the global radiopharmaceuticals market covers the following areas:

• Global radiopharmaceuticals market sizing
• Global radiopharmaceuticals market forecast
• Global radiopharmaceuticals market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global radiopharmaceuticals market vendors that include Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, Eckert and Ziegler AG, GE Healthcare Technologies, IBA Radiopharma Solutions, Jubilant Pharma Ltd., Lantheus, NorthStar Medical Radioisotopes, Novartis AG, NTP Radioisotopes SOC Ltd., PharmaLogic Holdings Corp., Radiomedix Inc., Siemens Healthineers AG, Sinotau Pharmaceuticals, Telix Pharmaceuticals Ltd.. Also, the global radiopharmaceuticals market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Source
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Radiopharmaceuticals Market 2020 - 2024
  • Historic Market Size - Data Table on Global Radiopharmaceuticals Market 2020 - 2024 ($ million)
• 5.2 Source segment analysis 2020 - 2024
  • Historic Market Size - Source Segment 2020 - 2024 ($ million)
• 5.3 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.4 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 AI Impact on Global Radiopharmaceuticals Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Source

• 8.1 Market segments
• 8.2 Comparison by Source
• 8.3 Cyclotrons - Market size and forecast 2025-2030
• 8.4 Nuclear reactors - Market size and forecast 2025-2030
• 8.5 Market opportunity by Source
  • Market opportunity by Source ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
• 9.2 Comparison by End-user
• 9.3 Diagnostics - Market size and forecast 2025-2030
• 9.4 Therapeutics - Market size and forecast 2025-2030
• 9.5 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

10 Market Segmentation by Application

• 10.1 Market segments
• 10.2 Comparison by Application
• 10.3 Oncology - Market size and forecast 2025-2030
• 10.4 Cardiology - Market size and forecast 2025-2030
• 10.5 Neurology - Market size and forecast 2025-2030
• 10.6 Market opportunity by Application
  • Market opportunity by Application ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Russia - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
  • 12.4.7 Spain - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Singapore - Market size and forecast 2025-2030
  • 12.5.7 Thailand - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Australia - Market size and forecast 2025-2030
  • 12.6.2 Brazil - Market size and forecast 2025-2030
  • 12.6.3 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.4 South Africa - Market size and forecast 2025-2030
  • 12.6.5 UAE - Market size and forecast 2025-2030
  • 12.6.6 Turkey - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Rising incidence of neurological disorders
  • Growing cancer cases and rising investment in oncology market
  • Minimal side effects of radiopharmaceuticals
• 13.2 Market challenges
  • Preparation and dispensing problems associated with radiopharmaceuticals
  • Shortage of radioisotopes
  • Regulatory hurdles regarding preparation of radiopharmaceuticals
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Production of cyclotron-based radiopharmaceuticals
  • Discovery and development of new radiopharmaceuticals
  • Improvement in healthcare infrastructure in emerging economies

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.5 Bracco S.p.A.
  • Bracco S.p.A. - Overview
  • Bracco S.p.A. - Product / Service
  • Bracco S.p.A. - Key offerings
  • SWOT
• 15.6 Cardinal Health Inc.
  • Cardinal Health Inc. - Overview
  • Cardinal Health Inc. - Business segments
  • Cardinal Health Inc. - Key news
  • Cardinal Health Inc. - Key offerings
  • Cardinal Health Inc. - Segment focus
  • SWOT
• 15.7 Curium Pharma
  • Curium Pharma - Overview
  • Curium Pharma - Product / Service
  • Curium Pharma - Key offerings
  • SWOT
• 15.8 Eckert and Ziegler AG
  • Eckert and Ziegler AG - Overview
  • Eckert and Ziegler AG - Business segments
  • Eckert and Ziegler AG - Key news
  • Eckert and Ziegler AG - Key offerings
  • Eckert and Ziegler AG - Segment focus
  • SWOT
• 15.9 GE Healthcare Technologies
  • GE Healthcare Technologies - Overview
  • GE Healthcare Technologies - Business segments
  • GE Healthcare Technologies - Key news
  • GE Healthcare Technologies - Key offerings
  • GE Healthcare Technologies - Segment focus
  • SWOT
• 15.10 IBA Radiopharma Solutions
  • IBA Radiopharma Solutions - Overview
  • IBA Radiopharma Solutions - Business segments
  • IBA Radiopharma Solutions - Key news
  • IBA Radiopharma Solutions - Key offerings
  • IBA Radiopharma Solutions - Segment focus
  • SWOT
• 15.11 Jubilant Pharma Ltd.
  • Jubilant Pharma Ltd. - Overview
  • Jubilant Pharma Ltd. - Product / Service
  • Jubilant Pharma Ltd. - Key offerings
  • SWOT
• 15.12 Lantheus
  • Lantheus - Overview
  • Lantheus - Business segments
  • Lantheus - Key offerings
  • Lantheus - Segment focus
  • SWOT
• 15.13 NorthStar Medical Radioisotopes
  • NorthStar Medical Radioisotopes - Overview
  • NorthStar Medical Radioisotopes - Product / Service
  • NorthStar Medical Radioisotopes - Key offerings
  • SWOT
• 15.14 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 15.15 NTP Radioisotopes SOC Ltd.
  • NTP Radioisotopes SOC Ltd. - Overview
  • NTP Radioisotopes SOC Ltd. - Product / Service
  • NTP Radioisotopes SOC Ltd. - Key offerings
  • SWOT
• 15.16 PharmaLogic Holdings Corp.
  • PharmaLogic Holdings Corp. - Overview
  • PharmaLogic Holdings Corp. - Product / Service
  • PharmaLogic Holdings Corp. - Key offerings
  • SWOT
• 15.17 Siemens Healthineers AG
  • Siemens Healthineers AG - Overview
  • Siemens Healthineers AG - Business segments
  • Siemens Healthineers AG - Key news
  • Siemens Healthineers AG - Key offerings
  • Siemens Healthineers AG - Segment focus
  • SWOT
• 15.18 Sinotau Pharmaceuticals
  • Sinotau Pharmaceuticals - Overview
  • Sinotau Pharmaceuticals - Product / Service
  • Sinotau Pharmaceuticals - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations